Danaher's (DHR) Cepheid subsidiary is being urged by global health groups to reduce the price of its GeneXpert mpox test to $5 from $20 to improve access in low-income nations, media outlets reported Friday.
The World Health Organization declared mpox a global public health emergency this summer as an outbreak in the Democratic Republic of Congo began spreading to neighboring countries, according to the reports.
GeneXpert is one of the three mpox tests approved for emergency use by the WHO. This test is crucial because machines that process the results are available across Africa, the reports said.
Danaher previously reduced its tuberculosis test prices to $7.97 last year following pressure from activists, Reuters said.
Cepheid did not immediately respond to MT Newswires' request for comment.
Price: 237.76, Change: -1.62, Percent Change: -0.68
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。